(S (NP (NNP Warfarin) (NN dosing)) (VP (VBZ remains) (ADJP (VBG challenging)) (PP (JJ due) (TO to) (NP (NP (VB narrow) (JJ therapeutic) (NN index)) (CC and) (NP (ADJP (RB highly) (JJ individual)) (NN variability))))) (. .))
(S (NP (NNP Incorrect) (NN warfarin) (NN dosing)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (VBG devastating) (JJ adverse) (NNS events))))) (. .))
(S (NP (NP (JJ Remarkable) (NNS efforts))) (VP (VBP have) (VP (VBN been) (VP (VBN made) (S (VP (TO to) (VP (VB develop) (NP (NP (DT the) (ADJP (NN machine) (NN learning) (VBN based)) (IN warfarin) (VBG dosing) (RP algorithms)) (VP (VBG incorporating) (NP (NP (JJ clinical) (NNS factors)) (CC and) (NP (NP (JJ genetic) (NNS variants)) (PP (JJ such) (IN as) (NP (NP (NNS polymorphisms)) (PP (IN in) (NP (NNP CYP2C9) (CC and) (NNP VKORC1))))))))))))))) (. .))
(S (NP (DT The) (ADJP (ADVP (RBS most) (RB widely)) (VBN validated)) (JJ pharmacogenetic) (NN algorithm)) (VP (VBZ is) (NP (NP (DT the) (NNP IWPC) (NN algorithm)) (VP (VBN based) (PP (IN on) (NP (NP (NN multivariate) (JJ linear) (NN regression)) (PRN (-LRB- -LRB-) (NP (NNP MLR)) (-RRB- -RRB-))))))) (. .))
(S (ADVP (RB However)) (, ,) (PP (IN with) (NP (RB only) (DT a) (JJ single) (NN algorithm))) (, ,) (NP (DT the) (NN prediction) (NN performance)) (VP (MD may) (VP (VB reach) (NP (DT an) (JJ upper) (NN limit)) (PP (ADVP (RB even)) (IN with) (NP (JJ optimal) (NNS parameters))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (JJ novel) (NN algorithms)) (VP (VBG using) (NP (JJ stacked) (NN generalization) (NNS frameworks)) (S (VP (TO to) (VP (VB estimate) (NP (DT the) (NN warfarin) (NN dose)))))) (, ,) (SBAR (WHPP (IN within) (WHNP (WDT which))) (S (NP (NP (JJ different) (NNS types)) (PP (IN of) (NP (NN machine) (VBG learning) (JJ algorithms)))) (VP (NN function) (ADVP (RB together)) (PP (IN through) (NP (DT a) (JJ meta-machine) (NN learning) (NN model))) (S (VP (TO to) (VP (VB maximize) (NP (DT the) (NN prediction) (NN accuracy)))))))))) (. .))
(S (PP (VBN Compared) (PP (TO to) (NP (DT the) (NNP IWPC-derived) (NNP MLR) (NN algorithm)))) (, ,) (NP (NP (NNP Stack) (CD 1) (CC and) (CD 2)) (VP (VBN based) (PP (IN on) (NP (JJ stacked) (NN generalization) (NNS frameworks))))) (VP (VBD performed) (ADVP (RB significantly) (RBR better)) (ADVP (JJ overall))) (. .))
(S (NP (NNP Subgroup) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (NN mean)) (PP (IN of) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (NP (WP$ whose) (VBD predicted) (NN dose)) (PP (IN of) (NP (NN warfarin))) (PP (IN within) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (DT the) (JJ actual) (JJ stable) (JJ therapeutic) (NN dose)))))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN percentage)) (PP (IN within) (NP (CD 20) (NN %)))) (-RRB- -RRB-)) (PP (IN for) (NP (NNP Stack) (CD 1))))))))) (VP (VBD was) (VP (VP (VBN improved) (PP (IN by) (NP (NP (CD 12.7) (NN %)) (PRN (-LRB- -LRB-) (PP (PP (IN from) (NP (CD 42.47) (NN %))) (PP (TO to) (NP (CD 47.86) (NN %)))) (-RRB- -RRB-)))) (PP (IN in) (NP (NNPS Asians)))) (CC and) (PP (PP (IN by) (NP (NP (CD 13.5) (NN %)) (PRN (-LRB- -LRB-) (PP (PP (IN from) (NP (CD 22.08) (NN %))) (PP (TO to) (NP (CD 25.05) (NN %)))) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ low-dose) (NN group)))) (PP (VBN compared) (PP (TO to) (NP (NP (NP (DT that)) (PP (IN for) (NP (NNP MLR)))) (, ,) (ADVP (RB respectively)))))))))) (. .))
(S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP$ our) (NN algorithms)) (VP (MD would) (ADVP (RB especially)) (VP (VB benefit) (NP (NP (NNS patients)) (VP (VBN required) (NP (JJ low) (JJ warfarin) (NN maintenance) (NN dose)))) (, ,) (SBAR (IN as) (S (NP (NP (JJ subtle) (NNS changes)) (PP (IN in) (NP (NN warfarin) (NN dose)))) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (JJ adverse) (JJ clinical) (NNS events)) (PRN (-LRB- -LRB-) (NP (NN thrombosis) (CC or) (NN bleeding)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ low) (NN dose)))))))))))))) (. .))
(S (NP (PRP$ Our) (NN study)) (VP (NNS offers) (NP (NP (VBP novel) (JJ pharmacogenetic) (NN algorithms)) (PP (IN for) (NP (JJ clinical) (NNS trials) (CC and) (NN practice))))) (. .))
